Physician profile
John Gomez
NPI 1710970199
$10,850.81
in general payments reported to CMS, 2019-2025
35 companies · $2,451 in 2025
The $2,451 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $657 · 2020: $1,075 · 2021: $1,280 · 2022: $1,516 · 2023: $2,519 · 2024: $1,352 · 2025: $2,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,268 · Education: $54.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,268.06 |
| Education | $54.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,780.77 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $2,170.08 | 2019-2025 | |
| Pfizer INC. | $961.96 | 2020-2025 | |
| Ucb, INC. | $793.85 | 2022-2025 | Bimzelx, Cimzia |
| Horizon Therapeutics Plc | $758.29 | 2019-2023 | Tepezza |
| Glaxosmithkline, LLC. | $627.38 | 2019-2025 | Benlysta |
| Janssen Biotech, INC. | $520.17 | 2019-2025 | Tremfya, Simponi, Stelara |
| Lilly USA, LLC | $270.36 | 2019-2023 | Taltz |
| Astrazeneca Pharmaceuticals Lp | $237.64 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $225.95 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $205.25 | 2021-2025 | Strensiq, Ultomiris |
| Mallinckrodt Hospital Products INC. | $188.39 | 2021-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $157.51 | 2022-2025 | Lupkynis |
| Shionogi INC | $132.25 | 2020-2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $132.24 | 2022-2023 | Arcalyst |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.47 | 2019-2024 | Cyltezo |
| Radius Health, INC. | $62.23 | 2019-2025 | Tymlos |
| Sandoz INC. | $60.76 | 2023 | Hyrimoz |
| Paratek Pharmaceuticals, INC. | $59.35 | 2022-2023 | Nuzyra |
| Mylan Institutional INC. | $49.36 | 2023 | Hulio |
| Ani Pharmaceuticals, INC. | $43.52 | 2023-2025 | Sovuna, Purified Cortrophin Gel |
| Scilex Pharmaceuticals INC. | $40.70 | 2024 | |
| Idorsia Pharmaceuticals US INC | $37.68 | 2022-2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $35.65 | 2024-2025 | Orencia |
| Vyera Pharmaceuticals, LLC | $22.75 | 2019 | |
| United Therapeutics Corporation | $21.01 | 2024 | Tyvaso |
| Biocon Biologics INC | $20.35 | 2023 | Hulio |
| Ultragenyx Pharmaceutical INC. | $20.16 | 2021 | |
| Hikma Pharmaceuticals USA | $19.49 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $18.61 | 2020 | |
| Tonix Medicines, INC. | $18.31 | 2025 | Tonmya |
| Celltrion USA INC. | $16.24 | 2023 | Yuflyma |
| Fidia Pharma USA INC. | $15.77 | 2023 | Hymovis |
| Integra Lifesciences Corporation | $13.89 | 2020 | |
| Viiv Healthcare Company | $11.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.